Michael Wong

Landmark Bio CEO Ran Zheng talks about the value of collaborating with best-in-class partners.

Chairman of the Harvard China Fund, Dr. William C. Kirby, talks about the potential impact on multinational western pharma firms of disruption in China.

Dr. Randall N. Hyer, SVP Global Medical Affairs at Moderna, talks about the strategies that have helped the company grow from startup to multi-billion-dollar firm in a decade.

Insights from AmerisourceBergen EVP and Chief Strategy Officer, Leslie Donato.

Harvard Business School Professor Joseph B. Fuller talks about the future prospects for pharma sales forces as they face more restrictions on accessing their target physicians and looming concerns of automation.

Amgen board member and serial CEO Fred Hassan talks about the three levers Fortune 500 C-suites should consider as they position their firms from pilots to enterprise-wide digital transformation.

Dr. Andrew (Drew) Otoo talks about how pharma employees can elevate their own value propositions.

Dr. Amy P. Abernethy talks about her career moves from academia to industry to the US Food & Drug Administation.

Rajit Kamal, Vice President, Asia Pacific for DePuy Synthes, a Johnson & Johnson company, offers recommendations for those wishing to secure an expatriate assignment with their company.

Mark Altmeyer, CEO of Arvelle, offers three recommendations for big pharma executives who are considering making the leap to startups.